Guggenheim 3rd Annual Healthcare Innovation Conference - PROKIDNEY CORP

Explicit Guidance:

• Enrollment Timeline: Completion of Phase 3 patient enrollment expected in Q1 2027.
• Regulatory Milestones: Anticipated accelerated approval readout for the EGFR slope endpoint in Q2 2027.
• Financial Position: Cash balance of $142 million as of September (sufficient to fund operations through mid-2027).
• Pricing Expectations: No specific numbers provided; pricing expected to align with current cell therapy benchmarks and rare disease products, contingent on data readout.

Business-Segment Outlook:

• Product Launch Strategy: Initial launch planned for late 2027 (post-Q2 readout) focusing on a "renal partnership network" of 8–10 high-volume centers with certified interventional radiologists.
• Manufacturing Capacity Ramp:
  • Year 1 (Launch): Capacity for 350 patients via existing Winston-Salem, NC facility.
  • Year 2: Tech transfer expansion to add 500 patient capacity (total 850).
  • Year 3: Further expansion to add 500 patient capacity (total 1,350).
  • Years 3–4: Target capacity of ~3,000 patients annually via facility expansion, CDMOs, or geographical expansion.
• Patient Segmentation: Phase 3 focus shifted to highest risk cohort (GFR < 30) based on Phase 2 data; Phase 3 eligibility requires GFR 20–35, Type 2 diabetes, and CKD diagnosis.

Market and Competitive Outlook:

• Market Size: Target addressable market (TAM) estimated at 1.1 million patients in the U.S. (Stage 3B/4 CKD with Type 2 diabetes).
• Clinical Differentiation: Product targets the unmet need for patients progressing despite standard of care (RAS inhibitors, SGLT2 inhibitors, GLP-1s); expected to be used as add-on therapy for high-risk patients who continue to decline.
• Competitive Moat: No direct competitors in nephrology for this cell therapy modality; defense via strong IP portfolio, proprietary know-how, and complex clinical trial execution barriers.
• Geographic Focus: Exclusive focus on the U.S. market for the near term due to the large, concentrated unmet need; strategic partnerships for international expansion will be explored post-U.S. launch.

Macro / Industry Outlook:

• Regulatory Environment: Favorable policy tailwinds from the 2019 Executive Order advancing American kidney health and the recent HHS Kidney Care Plan, which prioritize innovation to stabilize kidney function.
• Political Climate: Kidney disease receives bipartisan support, reducing regulatory and reimbursement risk.
• Standard of Care: Trial protocols and future labeling will mandate concurrent use of standard therapies (RAS inhibitors, SGLT2 inhibitors); GLP-1s are encouraged but randomization will balance usage.

Strategic Initiatives:

• Commercial Pathway: Development of a referral network connecting community nephrologists to interventional radiology centers of excellence to streamline patient identification and treatment.
• Manufacturing Scale-up: Phased expansion of the Winston-Salem facility starting Q4 2026 (tech transfer preparation) and Q1 2027 (expansion execution).
• Partnership Model: Open to strategic partnerships for non-U.S. markets; currently prioritizing organic U.S. execution.

Risks and Headwinds to Outlook:

• Execution Risk: Manufacturing capacity scaling and center network establishment (training, certification) must align with patient volume post-launch.
• Clinical Uncertainty: Accelerated approval relies on demonstrating a 1.5 mL/min/year difference in EGFR slope versus a 3.0 mL/min/year decline in the control group; failure to meet this statistical/clinical endpoint could delay or prevent approval.
• Reimbursement Timing: Pricing finalization and payer acceptance depend entirely on the Q2 2027 readout; commercial uptake may be delayed if data is not perceived as superior to existing small molecules/injections.
• Patient Identification: While TAM is large, actual commercial success depends on effective identification and referral of the specific high-risk cohort from community nephrologists to specialized centers.

Management Tone on the Future:

• Confidence: High confidence in the clinical outcome, citing a "50% difference" between treatment and control groups and strong KOL resonance with the data.
• Strategic Clarity: Management expresses strong conviction in the U.S.-first strategy and the specific "renal partnership" commercial model.
• Operational Discipline: Tone reflects a methodical approach to manufacturing scale-up and a cautious, data-dependent stance on pricing and international expansion.
• Timeline: Clear, specific milestones set for Q1 2027 (enrollment close) and Q2 2027 (data readout), with cash runway explicitly mapped to these events.